Health Trials

Low PD-L1 Expressing

1

Review clinical trials related to Low PD-L1 Expressing. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

Participants needed: 77
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Qilu Hospital of Shandong UniversityUpdated: May 7, 2026Locations: 29
Eligibility criteria

Aged 18-75 years, gender is not limited; [+9]

Allergic to any trial drug and its excipients, or serious allergy history, or co... [+15]

Read more